+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

First North American field release of a vaccinia-rabies glycoprotein recombinant virus

First North American field release of a vaccinia-rabies glycoprotein recombinant virus

Journal of Wildlife Diseases 34(2): 228-239

Following nearly 10 yr of extensive laboratory evaluation, a vaccinia-rabies glycoprotein (V-RG) vaccine was the first recombinant virus to undergo limited North American field release on 20 August 1990. The free-ranging raccoon population on Parramore Island (Virginia, USA) was exposed to a high density (10 baits/ha) of vaccine-laden baits distributed on a 300 ha vaccination area. An annual total of 887 raccoons were live-trapped for sedation, physical examination and blood collection for rabies antibody determination; there was no evidence of adverse effects or lesions due to the vaccine. Age and sex distributions, mean body weights, and live-capture histories of raccoons from the vaccination and non-baited control areas were compared. There were no statistically significant differences in survivorship between the baited and non-baited areas, nor between rabies antibody-positive and antibody-negative raccoons from the vaccination area. There was no trend in field mortality that suggested an association with either tetracycline or sulfadimethoxine, used as biomakers, or with vaccine contact determined by antibody status. No gross or histopathologic lesions due to the vaccine were demonstrated among a subsample of live-trapped raccoons collected for gross necropsy, biomarker analysis, histopathologic examination, and V-RG virus isolation attempts. Recovery of V-RG virus was limited to the tonsils of two biomarker-positive, clinically healthy raccoons collected from the vaccination area for postmortem examination on days 2 and 4 following bait distribution. These data reinforce the extensive body of safety data on the V-RG virus and extend it to include field evaluation where vaccine is offered free-choice in abundance, in baits designed to attract free-ranging raccoons, in a relatively simple ecosystem.

(PDF emailed within 0-6 h: $19.90)

Accession: 003142065

Download citation: RISBibTeXText

PMID: 9577769

DOI: 10.7589/0090-3558-34.2.228

Related references

Development of an oral wildlife rabies vaccine immunization of raccoons by a vaccinia rabies glycoprotein recombinant virus and preliminary field baiting trials. Chanock, R M , Et Al (Ed ) Vaccines, 87 Modern Approaches to New Vaccines: Prevention Of Aids And Other Viral, Bacterial, And Parasitic Diseases; Conference, Cold Spring Harbor, New York, Usa, 1986 Xxiii+461p Cold Spring Harbor Laboratory: Cold Spring Harbor, New York, Usa Illus Paper 389-392, 1987

Immunization against rabies using a vaccinia-rabies recombinant virus expressing the surface glycoprotein. Vaccines 85: molecular and chemical basis of resistance to parasitic bacterial and viral diseases edited by Richard A Lerner Robert M Chanock Fred Brown: 162, 1985

Towards rabies elimination in Belgium by fox vaccination using a vaccinia-rabies glycoprotein recombinant virus. Vaccine 12(15): 1368-1371, 1994

Immunization of foxes against rabies with a vaccinia recombinant virus expressing the rabies glycoprotein. Archives of Virology 102(3-4): 297-301, 1988

Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. 1984. Biotechnology 24: 508-512, 1992

New generation of rabies vaccine. Vaccinia-rabies glycoprotein recombinant virus. Applied Virology Research, Volume 1 New Vaccines and Chemotherapy: 69-90, 1988

Immunization against rabies using a recombinant vaccinia virus expressing the rabies glycoprotein. Genetical Research 45(2): 213, 1985

Rabies virus glycoprotein expressed in a vaccinia virus recombinant vaccine cross protects mice against unique genetic variants of rabies viruses isolated worldwide. Journal of Cellular Biochemistry Supplement 0(19A): 312, 1995

Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proceedings of the National Academy of Sciences of the United States of America 81(22): 7194-7198, 1984

Use of recombinant vaccinia-rabies glycoprotein virus for oral vaccination of wildlife against rabies: innocuity to several non-target bait consuming species. Journal of Wildlife Diseases 25(4): 540-547, 1989

Field use of a vaccinia-rabies recombinant vaccine for the control of sylvatic rabies in Europe and North America. Revue Scientifique et Technique 15(3): 947-970, 1996

Deliberate release of a recombinant vaccinia-rabies virus for vaccination of wild animals against rabies. Microbial Releases 1(4): 191-195, 1993

First field trial of fox vaccination against rabies using a vaccinia-rabies recombinant virus. Veterinary Record 123(19): 481-483, 1988

Potential long term ecological impacts of the release of a recombinant vaccinia-rabies virus for wildlife vaccination against rabies. Council of Europe Environmental Encounters Series, 20: 183-195, 1995